Allt inom Q3
Nanexa publishes interim report for January-September 2025
We have progressed with the optimization of our GLP-1 formulations, extended an existing commercial partnership, received approval for a PharmaShell patent application in Japan and submitted three new patent applications.
Nanexa publishes interim report for January-September 2024
Nanexas fas I-studie inom NEX-22 projektet för typ 2-diabetes har slutförts för samtliga patienter enligt plan.